The collaboration could provide Apogee with up to $1.3 billion in non-dilutive capital, including up to $800 million in synthetic royalty funding and access to $500 million in senior corporate debt.Apogee said the financing is expected to support the development and commercialization of Zumilokibart without future equity financing.Positive Phase 2 ResultsZumilokibart met all primary and secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial, supporting plans to advance the mid-dose regimen into Phase 3 trials in 2H 2026.At Week 16, 65.9% of patients receiving the mid-dose achieved EASI-75, compared with 23.4% on placebo. The high dose achieved 61.6%, while the low dose reached 50.5%.The mid dose also achieved IGA 0/1 response rates of 46.0% versus 10.9% for placebo, EASI-90 response rates of 47.4% versus 9.3%, and itch reduction response rates of 50.5% versus 13.9%.Safety And Expansion PlansZumilokibart was generally well tolerated, with the most common adverse events including nasopharyngitis, headache, and noninfectious conjunctivitis. The conjunctivitis rate for the planned Phase 3 mid-dose was 10.6%.Apogee plans to begin Phase 3 ADventure trials in atopic dermatitis in 2H 2026, while also advancing the Phase 2a ELEVATE trial in eosinophilic esophagitis and the ASPIRE Phase 2b asthma trial.CEO Michael Henderson said the data "could set a new standard of care for patients," while Chief Medical Officer Carl Dambkowski highlighted the potential for "a significant reduction in treatment burden for patients while delivering robust clinical activity."APGE Technical Outlook: Key Support, Resistance And MomentumCurrently, Apogee’s stock is trading 11.1% below its 20-day simple moving average (SMA) of $82.43 and 10.9% below its 50-day SMA of $82.25. The Relative Strength Index (RSI) sits at 50.79, indicating neutral momentum and suggesting the stock is neither overbought nor oversold at this time.